Business Trends– category –
-
US Space Force Awards SpaceX $4.16 Billion Contract for Airborne Target Tracking Satellite Constellation, Deployment by 2028
DefenseScoop USA Overview The U.S. Space Force has awarded SpaceX a monumental $4.16 billion contract to build a satellite constellation for tracking airborne targets by 2028, as part of its Space-Based Airborne Moving Target Indicator (... -
CordenPharma Announces Multi-Million Dollar Expansion of Oligonucleotide Manufacturing to Meet Soaring Demand for Nucleic Acid-Based Medicines
Pharmaceutical Technology Europe Overview CordenPharma announced a multi-million dollar investment to significantly expand its oligonucleotide manufacturing capacity across its global network. This strategic expansion aims to meet the in... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Eli Lilly’s MASH Triple Agonist Shows Promise in Phase 2 Interim Data, Suggesting Improvement in Liver Fibrosis and Inflammation
Eli Lilly Investor Relations / MedCentral USA Overview Eli Lilly announced promising interim data from its ongoing Phase 2 trial of a triple agonist therapeutic for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The data sugges... -
Kymera Therapeutics Initiates Phase 1 Clinical Trial for Oral STAT3 Degrader KT-XXX
Kymera Therapeutics Press Release USA Overview Kymera Therapeutics has announced the initiation of a Phase 1 clinical trial for its lead STAT3 degrader candidate, KT-XXX. The study aims to evaluate the safety, pharmacokinetics (PK), and ... -
Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation
Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA Overview Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseas... -
Moderna and BioNTech Forge Strategic Partnership to Co-Develop mRNA Therapeutics for Infectious Diseases
Fierce Biotech USA Overview Moderna and BioNTech, leaders in mRNA vaccine technology, have announced a strategic partnership to co-develop novel mRNA-based therapeutics targeting emerging infectious diseases. This collaboration aims to a... -
China’s Guoxiang Shiji to Build Integrated Solid-State Battery Industrial Complex in Shanghai Jiading, Unifying R&D to Mass Production
Gasgoo Express China Overview Guoxiang Shiji's new energy project has been officially settled in Jiading, Shanghai, with plans to build a solid-state battery industrial complex. This comprehensive facility will integrate a headquarters, ... -
Hongli Group Inc. Shifts Strategy to Solid-State Lithium Battery Technology, Appoints Dr. Philip A. Medina to Lead Development
PR Newswire USA Overview Hongli Group Inc., a cold roll formed steel profile manufacturer, announced a strategic shift to focus its energy storage initiatives on solid-state lithium battery technologies. This follows the establishment of...
